Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 5/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | USP1 | O94782 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.38 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13620400 | 0.91 | PRKCQ (0.46) | PRKCQDPP4BRD4USP1ADORA2A | |
| SCHEMBL13620209 | 0.89 | DDR1 (0.44) | PRKCQMCHR1ADRA2ANPY5R | |
| SCHEMBL13620261 | 0.89 | DDR1 (0.44) | PRKCQMCHR1ADRA2ANPY5R | |
| SCHEMBL13620044 | 0.89 | MCHR1 (0.46) | PRKCQDPP4USP1ADORA2AADORA1 | |
| SCHEMBL13620032 | 0.89 | MCHR1 (0.46) | PRKCQDPP4USP1ADORA2AADORA1 | |
| SCHEMBL12371645 | 0.88 | PRKCQ (0.43) | PRKCQDPP4BRD4USP1ADORA2A | |
| SCHEMBL12371632 | 0.88 | PRKCQ (0.43) | PRKCQDPP4BRD4USP1ADORA2A | |
| SCHEMBL12371661 | 0.88 | PRKCQ (0.43) | PRKCQDPP4BRD4USP1ADORA2A | |
| SCHEMBL13620302 | 0.87 | DPP4 (0.44) | PRKCQDPP4BRD4USP1ADORA2A | |
| SCHEMBL13620077 | 0.86 | PRKCQ (0.42) | PRKCQDPP4BRD4USP1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | PRKCQ 3/4885DPP4 3354/4885BRD4 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.